Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

153 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Fluctuation of physical function during chimeric antigen receptor T-cell therapy during rehabilitation intervention: Real-world data and risk factor analyses.
Hamada R, Arai Y, Kitawaki T, Nakamura N, Murao M, Matsushita M, Miyasaka J, Asano T, Jo T, Nishikori M, Kanda J, Mizumoto C, Yamashita K, Ikeguchi R, Takaori-Kondo A. Hamada R, et al. Among authors: nishikori m. EJHaem. 2024 Nov 4;5(6):1252-1259. doi: 10.1002/jha2.1043. eCollection 2024 Dec. EJHaem. 2024. PMID: 39691237 Free PMC article.
Synergistic involvement of the NZF domains of the LUBAC accessory subunits HOIL-1L and SHARPIN in the regulation of LUBAC function.
Toda Y, Fujita H, Mino K, Koyama T, Matsuoka S, Kaizuka T, Agawa M, Matsumoto S, Idei A, Nishikori M, Okuno Y, Osada H, Yoshida M, Takaori-Kondo A, Iwai K. Toda Y, et al. Among authors: nishikori m. Cell Death Dis. 2024 Nov 11;15(11):813. doi: 10.1038/s41419-024-07199-z. Cell Death Dis. 2024. PMID: 39528476 Free PMC article.
Tazemetostat for relapsed/refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan: 3-year follow-up for a phase II study.
Izutsu K, Ando K, Nishikori M, Shibayama H, Goto H, Kuroda J, Kato K, Imaizumi Y, Nosaka K, Sakai R, Abe M, Hojo S, Nakanishi T, Rai S. Izutsu K, et al. Among authors: nishikori m. Int J Hematol. 2024 Nov;120(5):621-630. doi: 10.1007/s12185-024-03834-9. Epub 2024 Aug 23. Int J Hematol. 2024. PMID: 39179948 Free PMC article.
Complete detection of FR1 to FR3 primer-based PCR patterns of immunoglobulin heavy chain rearrangement in the BIOMED-2 protocol is associated with poor prognosis in patients with diffuse large B-cell lymphoma.
Yabushita T, Shimomura Y, Maruoka H, Katoh D, Yamashita D, Satake H, Hiramoto N, Yoshioka S, Yonetani N, Nishikori M, Morimoto T, Imai Y, Ishikawa T. Yabushita T, et al. Among authors: nishikori m. EJHaem. 2024 Jun 18;5(4):698-708. doi: 10.1002/jha2.921. eCollection 2024 Aug. EJHaem. 2024. PMID: 39157631 Free PMC article.
KRAS G12 mutations as adverse prognostic factors in KMT2A-rearranged acute myeloid leukemia.
Iyoda S, Yoshida K, Shoji K, Ito N, Tanaka M, Nannya Y, Yamato G, Tsujimoto S, Shiba N, Hayashi Y, Shiozawa Y, Shiraishi Y, Chiba K, Okada A, Tanaka H, Miyano S, Koga Y, Goto H, Moritake H, Terui K, Ito E, Kiyokawa N, Tomizawa D, Taga T, Tawa A, Takita J, Nishikori M, Adachi S, Ogawa S, Matsuo H. Iyoda S, et al. Among authors: nishikori m. Leukemia. 2024 Jul;38(7):1609-1612. doi: 10.1038/s41375-024-02244-4. Epub 2024 Apr 18. Leukemia. 2024. PMID: 38632314 No abstract available.
End-of-treatment 18[F]-FDG PET can predict early progression in patients receiving bendamustine-rituximab for follicular lymphoma in first relapse: a prospective West Japan hematology Study Group (W-JHS) NHL01 trial.
Kato K, Izutsu K, Nishikori M, Shibayama H, Maeda Y, Yoshimura K, Tateishi U, Miyamoto T, Matsuda Y, Ishikawa J, Rai S, Takahashi T, Yamauchi T, Matsumura I, Akashi K, Kanakura Y, Suzumiya J. Kato K, et al. Among authors: nishikori m. Int J Hematol. 2024 Jun;119(6):677-685. doi: 10.1007/s12185-024-03738-8. Epub 2024 Mar 22. Int J Hematol. 2024. PMID: 38519820 Clinical Trial.
153 results